Difference between revisions of "Toremifene (Fareston)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.fareston.com/docs/GTX-Prescribing-Information.pdf Toremifene (Fareston) package insert]</ref><ref>[http://...") |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
| (16 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.fareston.com/docs/GTX-Prescribing-Information.pdf Toremifene (Fareston) package insert]</ref><ref>[ | + | Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.<ref name="insert">[http://www.fareston.com/docs/GTX-Prescribing-Information.pdf Toremifene (Fareston) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/toremifene.pdf Toremifene (Fareston) package insert (locally hosted backup)]</ref><ref>[http://fareston.com/ Fareston manufacturer's website]</ref> |
| − | <br>Route: | + | <br>Route: PO |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/bio/toremifene. | + | *[http://chemocare.com/bio/toremifene.asp Toremifene (Fareston) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/toremifene.asp Toremifene (Fareston) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/toremifene-patient-drug-information Toremifene (Fareston) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/toremifene-patient-drug-information Toremifene (Fareston) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/toremifene-patient-drug-information Toremifene (Fareston) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/toremifene-patient-drug-information Toremifene (Fareston) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1997-05-29: Initial approval for the treatment of metastatic [[breast cancer]] in postmenopausal women with [[Biomarkers#ER|estrogen-receptor]] [[Biomarkers#Expression|positive]] or [[Biomarkers#Unknown|unknown]] tumors. ''(Based on Gershanovich et al. 1997, Hayes et al. 1995, Pyrhönen et al. 1997)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1996-02-14: Initial authorization | ||
| + | *Indicated as first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Acapodene, Fareston, Farestone | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Oral medications]] | ||
| + | [[Category:Protein expression-specific medications]] | ||
| + | |||
| + | [[Category:Selective estrogen receptor modulators]] | ||
| + | |||
| + | [[Category:Breast cancer medications]] | ||
| + | |||
| + | [[Category:EMA approved in 1996]] | ||
| + | [[Category:FDA approved in 1997]] | ||
Latest revision as of 19:25, 23 June 2024
General information
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Toremifene (Fareston) patient drug information (Chemocare)[4]
- Toremifene (Fareston) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1997-05-29: Initial approval for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. (Based on Gershanovich et al. 1997, Hayes et al. 1995, Pyrhönen et al. 1997)
History of changes in EMA indication
- 1996-02-14: Initial authorization
- Indicated as first line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours.
Also known as
- Brand names: Acapodene, Fareston, Farestone